KRAS Cancer News & Updates

Once you know your options, the next question is: Am I eligible? Here’s how doctors typically determine if a patient qualifies for a clinical trial or specific therapy—regardless of cancer type. 6 things that matter...

..just been diagnosed—or are navigating next step—you’re not alone. Cancer care has changed dramatically in the last decade. Today, you may have more treatment choices than ever before. This post is designed to help you understand your options and feel confident asking the right questions.

💡 Why It Matters to Patients: Even if you’re not in the room, what happens at ASCO can shape your treatment options—now and in the future. KRAS-driven cancers (lung, colon, pancreatic, and rare cancers) are a major area of focus at ASCO. knowing what’s coming can help you: -Ask better questions - -Stay ahead of the curve - -Find hope in options you didn’t know existed- Gen-Me Medicine—where cancer care is about matching the right treatment to your unique molecular fingerpri

One of the patient voices from this documentary is Terri Conneran: Empowering the Patients For Precision Cancer Advocacy In the documentary, powerful stories from patients, industry experts, and healthcare providers about how precision medicine has empowered their healthcare decisions, providing renewed hope .

By KRAS Kickers – Cancer Knowledge + Research + Advocacy = Survivorship 📅 May 2025 | 🧬 Published in Blood Cancer Discovery 🔬...

Rare Pancreatic cancer trial comes to you! FGFR + KRAS

Low-Grade Serous Ovarian Cancer (LGSOC) is a rare, slow-growing type of ovarian cancer. It starts in the cells lining the ovaries, fallopian tubes, or peritoneum ...

KRAS Kickers is a cancer patient-led nonprofit organization that shares Knowledge of publicly available Research to empower patients and caregivers to Advocate for Survivorship. Our goal to kick cancer's KRAS!

Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus. Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference. Biomarkers provide the insights as to what is driving the cancer.

Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...